Zentalis Pharmaceuticals (ZNTL)
Develops azenosertib for biomarker-selected platinum-resistant ovarian cancer.
Something off on this page? Send us feedback.
Develops azenosertib, a WEE1 inhibitor in late-stage development for Cyclin E1-positive, platinum-resistant ovarian cancer. The clinical-stage business is concentrated on trial execution, companion-diagnostic validation, and regulatory review.
Develops azenosertib, an investigational WEE1 inhibitor for biomarker-selected, platinum-resistant ovarian cancer. The program includes enrolling DENALI parts 2b/2c, the confirmatory ASPENOVA study, and MUIR combination therapy. Earlier ROR1 antibody-drug conjugate assets and platform technology were exclusively licensed worldwide to Immunome as the portfolio narrowed around azenosertib.
Based in San Diego, California, the clinical-stage business depends on trial execution and regulatory outcomes in azenosertib studies. Companion-diagnostic validation remains ongoing in DENALI and ASPENOVA, tying development to biomarker testing and regulatory review. FDA lifted a partial clinical hold, clearing enrollment to resume with no change to the clinical plan.
Company facts
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $174.6M · Total debt $37.7M · Total assets $215.3M · Shareholders' equity $143.6M
- Revenue
- $0
- Operating income
- −$82.2M
- Net income
- −$77.6M
No dividends on record.
| Institutions104 holders · as of Mar 31, 2026 | 60.78% | 43.56M shares | |
| Insiders11 holders · as of Jun 18, 2026 | 4.63% | 3.32M shares | |
| Strategic holders2 holders · as of Aug 19, 2026 | 30.41% | 21.79M shares | |
| Otherremainder | 4.18% | 3.00M shares |
71.67M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Walters GroupStrategic10 percent owner | 24.90% | 17.84M | Form 4filed Aug 19, 2026 ↗ |
5AM Opportunities II (GP), LLCStrategic | 5.51% | 3.95M | 13Gfiled Dec 30, 2025 ↗ |
5Am Venture Management, LLCInstitution | 5.51% | 3.95M | 13Fas of Mar 31, 2026 |
Squadron Master Fund LPInstitution | 5.13% | 3.68M | 13Gfiled Mar 3, 2026 ↗ |
Squadron Capital Management LLCInstitution | 5.07% | 3.63M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 14, 2026 | Walters Group | 10 percent owner | +4,335,000 | $3.50 |
| Feb 9, 2026 | Julia Marie Eastland | director, officer: CEO & President | −889 | $2.39 |
| Feb 6, 2026 | Julia Marie Eastland | director, officer: CEO & President | −7,866 | $2.43 |
| Feb 10, 2026 | Vincent Vultaggio | officer: PAO and PFO | −6,894 | $2.42 |
| Feb 9, 2026 | Vincent Vultaggio | officer: PAO and PFO | −3,379 | $2.39 |
- AbbVie
Approved FRα-targeted therapy in platinum-resistant ovarian cancer
- Corcept Therapeutics
Approved nab-paclitaxel regimen for platinum-resistant ovarian cancer
- Sutro Biopharma
Registration-directed FRα ADC for platinum-resistant ovarian cancer
- Eli Lilly
Phase 3 FRα ADC program for platinum-resistant ovarian cancer
- Genelux
Phase 3 oncolytic-virus regimen for resistant ovarian cancer
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Zentalis Pharmaceuticals | $3.84 | +1.59% | $268.4M | — | — | — | — |
| AbbVie | $261.51 | −0.08% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Corcept Therapeutics | $110.40 | −0.10% | $11.94B | 262.9 | 27.7 | 14.4 | +31.7% |
| Sutro Biopharma | $20.47 | −1.68% | $198.1M | — | — | 4.3 | −84.6% |
| Eli Lilly | $1,165.80 | +0.55% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Genelux | $2.56 | −1.73% | $114.3M | — | — | 14,292.9 | −98.2% |
| Median | 73.7 | 27.7 | 13.7 | +10.2% |